LLY

785.76

-1.21%↓

JNJ

152.76

+0.26%↑

ABBV

186.41

-0.43%↓

NVO

68.78

+2.32%↑

UNH

307.81

+1.17%↑

LLY

785.76

-1.21%↓

JNJ

152.76

+0.26%↑

ABBV

186.41

-0.43%↓

NVO

68.78

+2.32%↑

UNH

307.81

+1.17%↑

LLY

785.76

-1.21%↓

JNJ

152.76

+0.26%↑

ABBV

186.41

-0.43%↓

NVO

68.78

+2.32%↑

UNH

307.81

+1.17%↑

LLY

785.76

-1.21%↓

JNJ

152.76

+0.26%↑

ABBV

186.41

-0.43%↓

NVO

68.78

+2.32%↑

UNH

307.81

+1.17%↑

LLY

785.76

-1.21%↓

JNJ

152.76

+0.26%↑

ABBV

186.41

-0.43%↓

NVO

68.78

+2.32%↑

UNH

307.81

+1.17%↑

Search

Zentalis Pharmaceuticals Inc

Abrir

1.27 -0.78

Visão Geral

Variação de preço das ações

24h

Atual

Mín

1.22

Máximo

1.28

Indicadores-chave

By Trading Economics

Rendimento

-807K

-48M

EPS

-0.67

Margem de lucro

-176.706

Funcionários

166

EBITDA

173K

-46M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+428.15% upside

Dividendos

By Dow Jones

Próximos Ganhos

8 de ago. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

720K

94M

Abertura anterior

2.05

Fecho anterior

1.27

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

Zentalis Pharmaceuticals Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

16 de set. de 2024, 11:52 UTC

Grandes Movimentos do Mercado

Zentalis Shares Rise After U.S. FDA Lifts Hold on Azenosertib Studies

Comparação entre Pares

Variação de preço

Zentalis Pharmaceuticals Inc Previsão

Preço-alvo

By TipRanks

428.15% parte superior

Previsão para 12 meses

Média 7.13 USD  428.15%

Máximo 10 USD

Mínimo 4 USD

Com base em 9 analistas de Wall Street que oferecem metas de preço de 12 meses para Zentalis Pharmaceuticals Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

9 ratings

5

Comprar

4

Manter

0

Vender

Pontuação Técnica

By Trading Central

1.23 / 1.45Suporte e Resistência

Curto Prazo

Very Strong Bearish Evidence

Médio Prazo

Weak Bullish Evidence

Longo Prazo

Weak Bearish Evidence

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.